Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients

International Clinical Psychopharmacology

Volumn 26, Issue 5, 2011, Pages 252-262

  Quera Salva, Maria Antonia ^a   Hajak, Goeran ^d   Philip, Pierre ^b   Montplaisir, Jaques ^e   Keufer Le Gall, Sophie ^c   Laredo, Judith ^c   Guilleminault, Christian ^f  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b HÔPITAL PELLEGRIN   (France)

^c IRIS Institut de Recherches Internationales Servier   (France)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f STANFORD UNIVERSITY   (United States)

Author keywords

agomelatine; antidepressant; escitalopram; polysomnography; sleep

Indexed keywords

AGOMELATINE; ESCITALOPRAM;

ADULT; ARTICLE; BRONCHITIS; DAYTIME SOMNOLENCE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; NIGHT SLEEP; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; RHINOPHARYNGITIS; SLEEP; SLEEP PATTERN; SOMNOLENCE; STATISTICAL ANALYSIS; VISUAL ANALOG SCALE;

ACETAMIDES; ADULT; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MELATONIN; MIDDLE AGED; POLYSOMNOGRAPHY; SEROTONIN UPTAKE INHIBITORS; SLEEP STAGES; TREATMENT OUTCOME; WAKEFULNESS;

EID: 80051718880     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328349b117     Document Type: Article

References (28)

1. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association.
2. Cho HJ, Lavretsky H, Olmstead R, Levin MJ, Oxman MN, Irwin MR (2008). Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry 165:1543-1550.
3. Dinges DF, Powell JW (1985). Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. Behav Res Methods Instrum Comput 17:652-655.
4. Djik DJ, Groeger JA, Stanley N, Deacon S (2010). Age-related reduction in daytime sleep propensity and nocturnal slow wave sleep. Sleep 33:211-223.
5. Goodwin GM, Emsley R, Rembry S, Rouillon F (2009). Agomelatine prevents relapse in patients with major depressive disorder, without evidence of discontinuation syndrome. J Clin Psychiatry 70:1128-1137.
6. Hale S, Corral RM, Mencacci C, Ruiz JS, Albarran Severo C, Gentil V, et al. (2010). Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 25:305-314.
7. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al. (1998). A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55:694-700. (Pubitemid 28364385)
8. Kasper S, Hajak G, Wulff K, Hoogendijk WI, Montejo AL, Smeraldi E, et al. (2010). Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle, depressive and anxiety symptoms in patients with major depressive disorder. A randomized, double-blind comparison with sertraline. J Clin Psychiatry 71:109-120.
9. Kennedy SH, Emsley R (2006). Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 16:93-100. (Pubitemid 43145814)
10. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010;24:479-499.
11. Kräuchi K, Cajochen C, Möri D, Graw P, Wirz-Justice A (1997). Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 272:R1178-R1188.
12. Kupfer DJ, Ehlers CL, Frank E, Grochocinski VJ, McEachran AB, Buhari A (1994). Persistent effects of antidepressants: EEG sleep studies in depressed patients during maintenance treatment. Biol Psychiatry 35:781-793. (Pubitemid 24165000)
13. Lemoine P, Guilleminault C, Alvarez E (2007). Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 68:1723-1732. (Pubitemid 350247502)
14. Loo H, Hale A, D'haenen H (2002). Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT (2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17:239-247.
15. Martinet L, Guardiola Lemaitre B, Mocaer E (1996). Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav 54:713-718. (Pubitemid 26258654)
16. Millan MJ, Brocco M, Gobert A, Dekeyne A (2005). Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 177:448-458.
17. Montgomery SA, Möller HJ (2009). Is the significance of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 24:111-118.
18. Ohayon MM, Roth T (2003). Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 37:9-15. (Pubitemid 35449766)
19. Olie JP, Kasper S (2007). Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661-673. (Pubitemid 47517525)
20. Quera Salva MA, Vanier B, Laredo J, Hartlety S, Chapotot F, Moulin C, et al. (2007). Major depressive disorder, sleep EEG, and agomelatine: an openlabel study. Int J Neuropsychopharmacol 10:691-696. (Pubitemid 47517524)
21. Rechtschaffen A, Kales A (1968). A manual of standardized terminology, techniques, and scoring system for sleep stages of human subjects. Los Angeles: UCLA Brain Information Service/Brain Research Institute.
22. Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, Armstrong SM (1995). Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology (Berl) 118:385-390.
23. Riemann D, Berger M, Voderholzer U (2001). Sleep and depression-results from psychobiological studies: an overview. Biol Psychol 57:67-103. (Pubitemid 32651895)
24. Sheehan DV, Lecrubier Y, Harnett Sheehan K, Janavs J, Weiller E, Hergueta T, et al. (1998). The Mini-International Neuropsychiatric Interview (M. I. N. I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22-33. (Pubitemid 29001829)
25. Wilson S, Argyropoulos S (2005). Antidepressants and sleep: a qualitative review of the literature. Drugs 65:927-947. (Pubitemid 40663621)
26. Wingen M, Bothmer J, Langer S, Ramaekers JG (2005). Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 66:436-443. (Pubitemid 40593571)
27. Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA (2000). Acute effects of Mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 48:75-78. (Pubitemid 30407153)
28. Winokur A, DeMartinis NA, McNally DP, Gary EM, Cormier JL, Gary KA (2003). Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 64:1224-1229.